Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:MLYS NYSE:NUVB NASDAQ:PHAR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.16-2.8%$3.54$2.45▼$4.14$250.77M0.24284,516 shs117,310 shsMLYSMineralys Therapeutics$38.50+7.2%$16.53$8.24▼$38.54$2.38B-0.292.45 million shs1.98 million shsNUVBNuvation Bio$3.35-4.0%$2.57$1.54▼$4.09$1.19B1.366.46 million shs5.99 million shsPHARPharming Group$14.87+2.4%$11.86$6.96▼$17.08$994.84M0.0510,808 shs8,474 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-2.77%-7.06%-6.51%-0.32%-13.90%MLYSMineralys Therapeutics+7.15%+33.40%+196.15%+147.59%+225.17%NUVBNuvation Bio-3.60%+13.75%+45.65%+52.27%+12.79%PHARPharming Group+0.47%+6.48%+12.40%+28.58%+112.73%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.16-2.8%$3.54$2.45▼$4.14$250.77M0.24284,516 shs117,310 shsMLYSMineralys Therapeutics$38.50+7.2%$16.53$8.24▼$38.54$2.38B-0.292.45 million shs1.98 million shsNUVBNuvation Bio$3.35-4.0%$2.57$1.54▼$4.09$1.19B1.366.46 million shs5.99 million shsPHARPharming Group$14.87+2.4%$11.86$6.96▼$17.08$994.84M0.0510,808 shs8,474 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-2.77%-7.06%-6.51%-0.32%-13.90%MLYSMineralys Therapeutics+7.15%+33.40%+196.15%+147.59%+225.17%NUVBNuvation Bio-3.60%+13.75%+45.65%+52.27%+12.79%PHARPharming Group+0.47%+6.48%+12.40%+28.58%+112.73%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0089.87% UpsideMLYSMineralys Therapeutics 2.80Moderate Buy$42.209.61% UpsideNUVBNuvation Bio 3.17Buy$7.50123.88% UpsidePHARPharming Group 3.00Buy$30.00101.75% UpsideCurrent Analyst Ratings BreakdownLatest AVIR, MLYS, PHAR, and NUVB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025MLYSMineralys TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $52.009/8/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.009/8/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$6.009/3/2025MLYSMineralys TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$15.00 ➝ $26.008/28/2025MLYSMineralys TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $43.008/13/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.008/8/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $7.006/25/2025NUVBNuvation BioJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$6.006/17/2025MLYSMineralys TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$42.006/17/2025NUVBNuvation BioRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$10.00 ➝ $6.006/11/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$5.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/AMLYSMineralys TherapeuticsN/AN/AN/AN/A$3.84 per shareN/ANUVBNuvation Bio$7.87M145.69N/AN/A$1.37 per share2.45PHARPharming Group$297.20M3.43$0.08 per share195.88$3.25 per share4.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)MLYSMineralys Therapeutics-$177.81M-$3.56N/AN/AN/AN/A-70.44%-65.51%11/10/2025 (Estimated)NUVBNuvation Bio-$567.94M-$0.63N/AN/AN/A-1,413.43%-46.14%-36.04%11/5/2025 (Estimated)PHARPharming Group-$11.84M-$0.13N/A495.67N/A-2.19%-3.31%-1.78%10/23/2025 (Estimated)Latest AVIR, MLYS, PHAR, and NUVB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025MLYSMineralys Therapeutics-$0.78-$0.66+$0.12-$0.66N/AN/A8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/A8/7/2025Q2 2025NUVBNuvation Bio-$0.17-$0.17N/A-$0.17$0.42 million$4.83 million7/31/2025Q2 2025PHARPharming Group-$0.10$0.06+$0.16$0.06$70.36 million$93.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AMLYSMineralys TherapeuticsN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.1719.17MLYSMineralys TherapeuticsN/A15.1215.12NUVBNuvation Bio0.139.399.38PHARPharming Group0.382.792.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%MLYSMineralys Therapeutics84.46%NUVBNuvation Bio61.67%PHARPharming Group0.03%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%MLYSMineralys Therapeutics33.24%NUVBNuvation Bio29.93%PHARPharming Group2.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableMLYSMineralys Therapeutics2866.30 million44.26 millionOptionableNUVBNuvation Bio60342.27 million239.83 millionOptionablePHARPharming Group28068.51 million67.10 millionNot OptionableAVIR, MLYS, PHAR, and NUVB HeadlinesRecent News About These CompaniesPharming Group promoted to the Euronext AMX® index4 hours ago | markets.businessinsider.comPharming Group N.V. (PHAR) Presents at H.C. Wainwright 27th Annual Global Investment Conference - SlideshowSeptember 8 at 2:02 PM | seekingalpha.comPharming Group (NASDAQ:PHAR) Shares Up 5% - Should You Buy?September 5, 2025 | marketbeat.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Down 73.1% in AugustSeptember 5, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What HappenedSeptember 4, 2025 | marketbeat.comPharming Group to present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | finance.yahoo.comPharming Group names new finance headSeptember 2, 2025 | msn.comPharming Group appoints Kenneth Lynard as Chief Financial OfficerSeptember 2, 2025 | markets.businessinsider.comWall Street Analysts See a 142.26% Upside in Pharming Group (PHAR): Can the Stock Really Move This High?August 22, 2025 | zacks.comPharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Sees Significant Growth in Short InterestAugust 17, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Trading 1.2% Higher - Still a Buy?August 16, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Should You Buy?August 13, 2025 | marketbeat.comPharming Group (NASDAQ:PHAR) Shares Gap Down - Should You Sell?August 12, 2025 | marketbeat.comPharming Group NV (PHARMA.XD) - Yahoo FinanceAugust 10, 2025 | finance.yahoo.comWall Street Analysts Think Pharming Group (PHAR) Could Surge 145.75%: Read This Before Placing a BetAugust 6, 2025 | zacks.comPharming Group N.V. Reports Strong Q2 EarningsAugust 4, 2025 | theglobeandmail.comPharming Group to participate in August investor conferenceAugust 4, 2025 | uk.finance.yahoo.comPharming Group Second Quarter 2025 Earnings: EPS: US$0.007 (vs US$0.002 loss in 2Q 2024)August 2, 2025 | finance.yahoo.comPharming Group N.V. (PHAR) Q2 2025 Earnings Call TranscriptAugust 1, 2025 | seekingalpha.comPharming Group N.V. 2025 Q2 - Results - Earnings Call PresentationAugust 1, 2025 | seekingalpha.comNew Strong Buy Stocks for August 1stAugust 1, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Biotech Catalysts Present Major OpportunityBy Nathan Reiff | August 25, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 20253 Under-the-Radar Biotechs Under $5 That Could Soar 200%By Chris Markoch | September 9, 2025CoreWeave and Madrigal's Insider Trades Flash Bullish SignalsBy Leo Miller | September 10, 2025AVIR, MLYS, PHAR, and NUVB Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.16 -0.09 (-2.77%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$3.15 -0.01 (-0.32%) As of 08:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Mineralys Therapeutics NASDAQ:MLYS$38.50 +2.57 (+7.15%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$38.46 -0.05 (-0.12%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.Nuvation Bio NYSE:NUVB$3.35 -0.14 (-4.01%) Closing price 09/9/2025 03:59 PM EasternExtended Trading$3.36 +0.02 (+0.45%) As of 09:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.Pharming Group NASDAQ:PHAR$14.87 +0.35 (+2.41%) Closing price 09/9/2025 03:53 PM EasternExtended Trading$14.90 +0.03 (+0.20%) As of 09:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
